Interview with Murtaza Khorakiwala, Managing Director, Wockhardt
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
The Dishman Group was founded in 1983 by Shri Janmejay R. Vyas, Managing Director of the Dishman Group. Since the beginning, the focus of the Dishman Group has been on research and development of various in-house technologies for the manufacture of quaternary ammonium compounds (quats) and active pharmaceutical ingredients.
The first facility of the Dishman Group was built in 1987 in Naroda; in 1996 the company initiated its expansion at Bavla where it is currently headquartered. Through several acquisitions, the Dishman Group became a global company with multiple manufacturing facilities in India, Europe and China serving pharmaceutical and biopharmaceutical companies.
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? There has been…
“India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub.” For Dilip Shah, General…
See our Cookie Privacy Policy Here
